Home › Funds › Patient Square Capital LP › ALLO
Patient Square Capital LP position in ALLO
ALLOGENE THERAPEUTICS INC · Health Care
Patient Square Capital LP reported holding 4,550,000 shares of ALLO (ALLOGENE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$7.3M, representing 1.16% of its reported portfolio and ranking #20 among its reported holdings. Patient Square Capital LP has disclosed ALLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's ALLO position evolved
Patient Square Capital LP first disclosed a stake in ALLO in Q4 2024 at 1,489,909 shares (US$3.2M). The position peaked in Q2 2026 at 5,050,000 shares, worth US$10.5M. Across 8 filings, Patient Square Capital LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,550,000 shares valued at US$7.3M — a reduction of -500,000 shares quarter over quarter.. Notable position changes include a 59% increase in Q1 2025 (shares fell 23% over the following quarter), a 66% increase in Q4 2025 (shares rose 78% over the following quarter), a 46% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.49M | $3.17M | New |
| Q1 2025 | 2.37M | $3.46M | Add |
| Q2 2025 | 2.63M | $2.98M | Add |
| Q3 2025 | 2.98M | $3.70M | Add |
| Q4 2025 | 4.96M | $6.80M | Add |
| Q1 2026 | 3.45M | $8.42M | Reduce |
| Q2 2026 | 5.05M | $10.50M | Add |
| Q3 2026 | 4.55M | $7.28M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALLO and 13F data
ALLO (ALLOGENE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in ALLO — the largest reported positions include Frazier Life Sciences Management, L.P. (US$46.7M), TPG GP A, LLC (US$38.9M), PFIZER INC (US$36.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALLO
- Frazier Life Sciences Management, L.P. 22.45M sh · $46.69M · Q2 2026
- TPG GP A, LLC 18.72M sh · $38.93M · Q2 2026
- PFIZER INC 22.03M sh · $36.35M · Q3 2026
- Sio Capital Management, LLC 13.32M sh · $27.71M · Q2 2026
- GordonMD Global Investments LP 5.30M sh · $11.02M · Q2 2026
- Wildcat Capital Management, LLC 2.92M sh · $4.67M · Q3 2026
- DAFNA Capital Management LLC 2.00M sh · $4.16M · Q2 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held ALLO?
Patient Square Capital LP has disclosed ALLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Patient Square Capital LP's current position in ALLO?
As of Q3 2026, Patient Square Capital LP holds 4.55M shares of ALLO (ALLOGENE THERAPEUTICS INC), valued at $7.28M, representing 1.16% of its reported portfolio and ranking #20.
Has Patient Square Capital LP been buying or selling ALLO?
In the latest 13F filing (Q3 2026), Patient Square Capital LP reduced its position in ALLO. The position peaked in Q2 2026 at 5.05M shares.
Which other funds hold ALLO?
Other major institutional holders of ALLO include Frazier Life Sciences Management, L.P., TPG GP A, LLC, PFIZER INC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.